In PIII BE BRIGHT study, >80% of patients who achieved complete skin clearance (PASI 100) after 16 weeks of bimekizumab treatment maintained PASI 100 response and health-related QOL outcomes for three years with continuous maintenance dosing .
In PIII BE BRIGHT study, > 90% of patients who achieved clear or almost clear skin (IGA 0/1) after 16 weeks of bimekizumab treatment maintained these responses through to two years with continuous maintenance dosing .
Results of PIII BE RADIANT published in NEJM .
Results of PIII BE SURE RCT published in NEJM .
Published PIII trial BE SURE met its secondary endpoints. The safety profile of bimekizumab was consistent with earlier clinical studies with no new safety signals identified 
Published PIII trial BE RADIANT results showed pts treated with bimekizumab achieved complete skin clearance (PASI 100) at week 16 of 61.7% vs 48.9% for pts treated with secukinumab (p<0.001). Superior levels of PASI 100 were also demonstrated up to week 48 of therapy. The trial also met all secondary endpoints. The most common treatment-emergent adverse events (TEAEs) with bimekizumab were upper respiratory tract infections (38.9%), oral candidiasis (19.3%) and urinary tract infection (6.7%). Oral candidiasis cases were predominantly mild or moderate and none led to discontinuation. Over 48 weeks, the incidence of serious TEAEs was 5.9% with bimekizumab vs 5.7% with secukinumab. [16, 17]
In PIII trial BE VIVID (n=567), bimekizumab was more effective than ustekinumab and placebo in terms of achievement of PASI90 at week 16 (85% versus 50% and 5%, respectively; both p<0.0001) and IGA response of clear or almost clear (84% versus 53% and 5%; both p<0.0001) .
In PIII trial BE READY (n=435), PASI90 was achieved in 91% of patients receiving the IL-17F and IL-17A inhibitor bimekizumab (320mg every 4 weeks) compared to 1% receiving placebo (p<0.0001), and an IGA score of 0 or 1 was achieved in 93% v 1%, respectively (p<0.0001) .
More detailed results have been released for the PIII BE SURE study; 86.2% of patients treated with bimekizumab achieved almost clear skin (PASI 90), compared with 47.2% of patients treated with adalimumab at week 16 (p<0.001).1 Additionally, 85.3% of patients treated with bimekizumab achieved IGA0/1, versus 57.2% of patients treated with adalimumab at week 16 (p<0.001) .
PIII trial BE RADIANT met its primary endpoint at week 16 with statistical significance, demonstrating the superiority of bimekizumab over secukinumab for complete skin clearance, as measured by a 100 percent improvement in the Psoriasis Area and Severity Index (PASI 100) .
In PIII trial BE READY randomized withdrawal study, participants were randomized to bimekizumab 320mg Q4W or placebo for the first 16 weeks. Bimekizumab was superior to placebo in achieving PASI 90 and IGA 0/1 at week 16; over 90 percent of participants receiving bimekizumab achieved PASI 90 or IGA 0/1, while 68.2 percent achieved complete skin clearance (all p<0.001) .
PIII active-controlled BE SURE study compared bimekizumab to adalimumab in the treatment of adults with moderate-to-severe plaque psoriasis. BE SURE met its co-primary endpoints at week 16, demonstrating superiority of bimekizumab to adalimumab in achieving at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90). The study also met all secondary endpoints with statistical significance, including superior total skin clearance at weeks 16 and 24, as measured by PASI 100 .
UCB has announced positive results from the PIII BE READY study; bimekizumab met its co-primary endpoints of at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1) at week 16, compared to placebo .
PIII BE VIVID study (n=570) meets primary endpoint .
In PIII trial BE VIVID with active comparator ustekinumab, patients treated with bimekizumab 320 mg every four weeks (Q4W) achieved significantly superior skin clearance than those receiving placebo or ustekinumab at week 16, as measured by PASI 90 and IGA 0/1 .
PIII BE BRIGHT trial to evaluate the long-term safety and tolerability of bimekizumab in adults with moderate to severe chronic plaque psoriasis starts (NCT03598790; PS0014). The trial is enrolling 1,120 patients in the US and Japan, and is expected to complete collection of primary outcome data in May 21 .
PIII BE RADIANT trial to compare the efficacy of bimekizumab versus secukinumab in patients with moderate to severe chronic plaque psoriasis starts (PS0015; NCT03536884). The study intends to enrol 700 patients in the US .
PIII BE READY trial to compare the efficacy of bimekizumab versus placebo in patients with moderate to severe plaque psoriasis starts (PS0013; NCT03410992). The trial will enrol 435 patients in the US, and is expected to complete collection of primary outcome data in Feb 19 .
PIII BE SURE trial to compare the efficacy and safety of bimekizumab versus adalimumab in patients with moderate to chronic plaque psoriasis starts (PS0008; NCT03412747). It will enrol 450 patients in the US .
PIII BE VIVID trial to compare the efficacy of bimekizumab versus placebo and an active comparator ustekinumab, in the treatment of subjects with moderate to severe chronic plaque psoriasis starts (NCT03370133; PS0009). The trial is enrolling 560 patients in the US .